282.85

2.26% -6.54

Alnylam Pharmaceuticals Inc (ALNY)

Overview News Price History Option Chain Financials Why ALNY Down? Discussions Forecast

Alnylam Pharmaceuticals Inc stock is traded at $282.85, with a volume of 1.42M. It is down -2.26% in the last 24 hours and down -3.14% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Previous Close:

$289.39

Open:

$288.96

24h Volume:

1.42M

Relative Volume:

1.28

Market Cap:

$37.76B

Revenue:

$4.29B

Net Income/Loss:

$577.22M

P/E Ratio:

67.21

EPS:

4.2086

Net Cash Flow:

$641.34M

1W Performance:

-6.67%

1M Performance:

-3.14%

6M Performance:

-28.85%

1Y Performance:

-7.16%

1-Day Range:

$281.76

$291.28

1-Week Range:

$281.76

$303.57

52-Week Range:

$281.76

$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name

Alnylam Pharmaceuticals Inc

Sector

Healthcare (1109)

Industry

Biotechnology (621)

Phone

(617) 551-8200

Address

675 WEST KENDALL STREET, CAMBRIDGE, MA

Employee

2,500

Twitter

@alnylam

Next Earnings Date

2026-07-30

Latest SEC Filings

ALNY's Discussions on Twitter

Compare ALNY vs VRTX, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALNY Alnylam Pharmaceuticals Inc	282.85	37.76B	4.29B	577.22M	641.34M	4.2086
VRTX Vertex Pharmaceuticals Inc	444.93	112.92B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	612.14	64.18B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	893.52	55.57B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	153.87	32.71B	742.00K	-1.37B	-1.07B	-7.0731

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Downgrade	Jefferies	Buy → Hold
Jan-28-26	Resumed	Barclays	Overweight
Jan-07-26	Resumed	Oppenheimer	Outperform
Aug-04-25	Upgrade	Oppenheimer	Perform → Outperform
Aug-04-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Jul-30-25	Resumed	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Mar-31-25	Initiated	Redburn Atlantic	Buy
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy
Feb-16-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-26-23	Initiated	SMBC Nikko	Neutral
Mar-21-23	Initiated	Bernstein	Outperform
Jan-18-23	Initiated	Canaccord Genuity	Buy
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-01-22	Initiated	Citigroup	Buy
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Nov-22-21	Upgrade	Goldman	Neutral → Buy
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-01-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-04-21	Upgrade	UBS	Neutral → Buy
Aug-04-21	Downgrade	Piper Sandler	Overweight → Neutral
Feb-22-21	Downgrade	Guggenheim	Buy → Neutral
Feb-12-21	Downgrade	Citigroup	Buy → Neutral
Feb-12-21	Reiterated	H.C. Wainwright	Buy
Jan-25-21	Downgrade	BMO Capital Markets	Outperform → Market Perform
Sep-30-20	Resumed	Berenberg	Hold
Sep-08-20	Initiated	Citigroup	Buy
Aug-11-20	Downgrade	Oppenheimer	Outperform → Perform
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
May-07-20	Downgrade	JP Morgan	Overweight → Neutral
Apr-24-20	Resumed	Evercore ISI	Outperform
Mar-19-20	Initiated	Berenberg	Buy
Dec-19-19	Reiterated	Chardan Capital Markets	Buy
Nov-20-19	Initiated	Oppenheimer	Outperform
Nov-13-19	Initiated	BofA/Merrill	Buy
May-23-19	Resumed	Goldman	Neutral
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-06-19	Upgrade	Evercore ISI	In-line → Outperform
Mar-05-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-23-19	Initiated	UBS	Neutral
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-13-18	Reiterated	Stifel	Buy
Aug-07-18	Upgrade	Stifel	Hold → Buy
May-04-18	Reiterated	Stifel	Hold
Mar-28-18	Initiated	Evercore ISI	In-line

View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

Jun 13, 2026

Understanding Momentum Shifts in (ALNY) - Stock Traders Daily

Jun 13, 2026

Alnylam Pharmaceuticals stock hits 52-week low at $282.71 By Investing.com - Investing.com Nigeria

Jun 13, 2026

Jun 12, 2026

Alnylam Pharmaceuticals stock hits 52-week low at $282.71 - Investing.com

Jun 12, 2026

Alnylam to Host Tenth “RNAi Roundtable” Webcast Series - BioSpace

Jun 12, 2026

Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? - The Globe and Mail

Jun 12, 2026

Andra AP fonden Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Jun 12, 2026

Jun 11, 2026

What Does the Alnylam-Inceptive AI Deal Entail - Kavout

Jun 11, 2026

Motley Fool Asset Management LLC Purchases 3,480 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Jun 11, 2026

GENESIS Pharma Broadens Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics Across Nordic Markets - World Business Outlook

Jun 11, 2026

Jun 10, 2026

Alnylam Pharmaceuticals unveils 2030 targets, betting on AMVUTTRA and pipeline readouts - MSN

Jun 10, 2026

A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2030 Goals And AI Partnership Refocus Growth Expectations - simplywall.st

Jun 10, 2026

Genesis and Alnylam Expand Partnership to Commercialize RNAi Therapeutics for Nordic Region - Contract Pharma

Jun 10, 2026

Alnylam Stock Is Running Its Own Race. Here’s What That Means for Your Portfolio. - Trefis

Jun 10, 2026

Genesis Pharma expands Alnylam partnership to Nordic markets By Investing.com - Investing.com South Africa

Jun 10, 2026

Junevity Partners with Sunrise BioVentures as Advisors to Accelerate siRNA Therapeutic Development - Business Wire

Jun 10, 2026

GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region - Stock Titan

Jun 10, 2026

Alnylam Stock Is Running Its Own Race. Here's What That Means for Your Portfolio. - Trefis

Jun 10, 2026

Jun 09, 2026

Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts - Yahoo Finance

Jun 09, 2026

Fiera Capital Corp Purchases 16,916 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Jun 09, 2026

Alnylam to collaborate with Inceptive to use AI for RNAi therapy development - MSN

Jun 09, 2026

Jun 08, 2026

Alnylam Slides as Investors Refocus on Near-term Amvuttra Growth After Recent AI-deal Headlines - Moomoo

Jun 08, 2026

Bloom Energy, Astera Labs, Alnylam, Reddit could be among next adds to S&P 500 - MSN

Jun 08, 2026

Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500 - Barron's

Jun 08, 2026

City banks nearly $100M for next-gen RNAi drugs - BioPharma Dive

Jun 08, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Down 5%What's Next? - MarketBeat

Jun 08, 2026

Alnylam slides as investors refocus on near-term Amvuttra growth after recent AI-deal headlines - Quiver Quantitative

Jun 08, 2026

Capital International Inc. CA Sells 16,086 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Jun 08, 2026